- Mbala-Kingebeni, Placide;
- Pratt, Catherine;
- Ruffin, Mbusa Mutafali;
- Pauthner, Matthias G;
- Bile, Faustin;
- Ndaye, Antoine Nkuba;
- Black, Allison;
- Lusamaki, Eddy Kinganda;
- Faye, Martin;
- Aziza, Amuri;
- Diagne, Moussa M;
- Mukadi, Daniel;
- White, Bailey;
- Hadfield, James;
- Gangavarapu, Karthik;
- Bisento, Nella;
- Kazadi, Donatien;
- Nsunda, Bibiche;
- Akonga, Marceline;
- Tshiani, Olivier;
- Misasi, John;
- Ploquin, Aurelie;
- Epaso, Victor;
- Paka, Emilia Sana;
- N’kasar, Yannick Tutu Tshia;
- Mambu, Fabrice;
- Edidi, Francois;
- Matondo, Meris;
- Bula, Bula;
- Diallo, Boubacar;
- Keita, Mory;
- Belizaire, Marie Roseline Darnycka;
- Fall, Ibrahima Soce;
- Yam, Abdoulaye;
- Sabue, Mulangu;
- Rimion, Anne W;
- Salfati, Elias;
- Torkamani, Ali;
- Suchard, Marc A;
- Crozier, Ian;
- Hensley, Lisa;
- Rambaut, Andrew;
- Faye, Ousmane;
- Sall, Amadou;
- Sullivan, Nancy J;
- Bedford, Trevor;
- Andersen, Kristian G;
- Wiley, Michael R;
- Ahuka-Mundeke, Steve;
- Tamfum, Jean-Jacques Muyembe
During the 2018-2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus-based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)-specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.).